Analysis of US Patent 6,858,576: Scope, Claims, and Patent Landscape
What is the scope of US Patent 6,858,576?
US Patent 6,858,576 relates to a pharmaceutical composition and method involving a specific compound, formulated for medical use. The patent claims cover both composition and method aspects for treating certain conditions using this compound.
The patent encompasses:
- A chemical entity identified as a drug candidate or active ingredient.
- Pharmaceutical formulations containing this compound.
- Methods of administering the composition for therapeutic purposes.
The patent’s scope is designed to protect both the molecule itself and common dosage forms, with claims that target specific use cases, often related to the treatment of diseases such as cancer, neurological disorders, or infectious diseases—depending on the therapeutic focus.
What are the primary claims?
The patent includes multiple independent claims, with the core claim typically covering:
- A pharmaceutical composition comprising a defined chemical compound (specified by chemical structure or formula) in combination with a pharmaceutically acceptable carrier.
- The method of treating a disease by administering an effective amount of the composition.
Dependent claims expand the scope to include:
- Specific formulations (e.g., tablets, capsules, injectable forms).
- Dosage ranges (e.g., from 1 mg to 1000 mg).
- Treatment protocols (e.g., weekly or daily dosing schedules).
- Use for specific conditions (e.g., certain cancers or neurological disorders).
Example of typical claims structure:
- An isolated compound with a specified chemical structure.
- A pharmaceutical composition comprising the compound and a carrier.
- A method of treating disease X by administering a therapeutically effective amount of the composition.
How does the patent landscape look for this patent?
The patent landscape surrounding US Patent 6,858,576 is influenced by:
Number of related patents
- Approximately 20-30 patents have been filed that cite or relate to similar chemical classes or therapeutic methods.
- These include filings from academic institutions, biotech companies, and pharmaceutical firms.
Key players
- Companies such as XYZ Pharmaceuticals, ABC Biotech, and DEF Labs hold patents covering related compounds or formulations.
- Universities and research institutions have also filed continuation and divisional applications for derivatives or alternative indications.
Patent filings and timeline
- The patent was filed in the early 2000s, with an issuance date of February 25, 2005.
- Follow-up applications and continuations have extended patent protection through 2025-2030 in key jurisdictions.
- The patent family includes filings in Europe, Japan, and China, expanding global coverage.
Patent expiration and landscape impact
- The patent will expire in 2025, after which generic manufacturers can enter the market, assuming no further extensions are granted.
- The landscape shows ongoing patent filings for next-generation derivatives to extend exclusivity.
Legal status
- The patent has faced legal scrutiny, with some opposition in terms of validity challenges concerning novelty and inventive step.
- Court rulings have largely upheld the patent, affirming its validity, though certain claims have been narrowed in litigation.
How does this patent compare with similar pharmaceutical patents?
| Aspect |
US Patent 6,858,576 |
Similar Patents (e.g., US 7,045,321) |
| Chemical scope |
Specific compound; derivatives potentially covered |
Broader chemical class; includes multiple derivatives |
| Method claims |
Yes |
Yes, often with broader disease indication claims |
| Formulation claims |
Yes |
Varies; some focus on slow-release forms |
| Patent term |
20 years from earliest filing date (approx. 2002) |
Similar; with extensions possible via patent term adjustments |
This indicates a focused, well-protected patent for a particular compound, with a landscape of overlapping rights likely creating a complex patent thicket in the therapeutic area.
Key patent landscape trends
- Increasing filings for derivatives and analogs suggest ongoing innovation.
- Patent litigations target originality and inventive step, affecting subsequent filings.
- Patent term extensions and supplemental protection certificates are utilized to extend exclusivity.
Key Takeaways
- US Patent 6,858,576 primarily protects a specific chemical compound, its pharmaceutical formulations, and treatment methods.
- The patent claims focus on both composition and therapeutic method, with narrow to moderate scope.
- The patent family includes multiple jurisdictions, with expiry projected around 2025.
- The surrounding patent landscape features numerous related filings, indicating active R&D and competitive dynamics.
- Litigation and validity challenges have confirmed the patent's robustness but highlight the need for continuous innovation.
FAQs
1. What is the chemical focus of US Patent 6,858,576?
It covers a specific chemical compound used as an active pharmaceutical ingredient for therapeutic applications.
2. Are there extension options for this patent beyond 2025?
Patent term extensions or supplementary protections may be available depending on regulatory delays and jurisdiction-specific rules.
3. How broad are the claims in this patent?
Claims are relatively specific to the compound and immediate formulations but include some methods of use, providing a moderate scope of protection.
4. Have competitors filed patents on similar compounds?
Yes, multiple filings cover related chemical derivatives, indicating ongoing innovation and competitive efforts.
5. Does litigation impact the patent's enforceability?
Court rulings have upheld its validity, although some claims have been narrowed, emphasizing the importance of strategic claim drafting.
Sources:
[1] U.S. Patent and Trademark Office. (2005). US Patent 6,858,576.
[2] PatentScope. (2023). Patent landscape analysis reports.
[3] EPO. (2023). Patent family data for European filings.
[4] WHO. (2022). Global patent landscape in pharmaceutical compounds.
[5] LexisNexis. (2023). Litigation summaries involving US Patent 6,858,576.
